SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-010576
Filing Date
2024-02-06
Accepted
2024-02-06 16:30:11
Documents
16
Period of Report
2024-01-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea192988-8k_aditxtinc.htm   iXBRL 8-K 32006
2 FORM OF AMENDMENT NO. 3 TO JANUARY 2024 SECURED NOTES ea192988ex10-1_aditxtinc.htm EX-10.1 5171
3 FORM OF AMENDMENT NO. 2 TO SEPTEMBER 2024 SECURED NOTES ea192988ex10-2_aditxtinc.htm EX-10.3 4256
  Complete submission text file 0001213900-24-010576.txt   220459

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE adtx-20240131.xsd EX-101.SCH 3009
5 XBRL LABEL FILE adtx-20240131_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE adtx-20240131_pre.xml EX-101.PRE 22355
17 EXTRACTED XBRL INSTANCE DOCUMENT ea192988-8k_aditxtinc_htm.xml XML 3705
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

IRS No.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39336 | Film No.: 24600683
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)